SCHEMBL10156263

SCHEMBL10156263

CCOC(=O)Cc1cc(Br)c(OC)c2ncccc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.43
MAPT P10636 7/20 0.43
PTK2 Q05397 1/20 0.41
ALDH1A1 P00352 8/20 0.41
KDM4E B2RXH2 8/20 0.41
RXFP1 Q9HBX9 3/20 0.41
DPP4 P27487 2/20 0.41
TP53 P04637 3/20 0.40
HPGD P15428 2/20 0.40
HTT P42858 2/20 0.40
HSD17B10 Q99714 2/20 0.40
KMT2A Q03164 4/20 0.40
L3MBTL1 Q9Y468 3/20 0.40
TDP1 Q9NUW8 2/20 0.40
MPI P34949 1/20 0.40
NPSR1 Q6W5P4 3/20 0.40
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10156194 0.86 MAPT (0.43) PKMMAPTPTK2ALDH1A1KDM4E
SCHEMBL10156259 0.78 KDM4E (0.43) MAPTALDH1A1KDM4ERXFP1TP53
SCHEMBL13255550 0.76 KDM4E (0.45) MAPTALDH1A1KDM4ERXFP1TP53
SCHEMBL4949470 0.75 KDM4E (0.62) MAPTALDH1A1KDM4ETP53HTT
SCHEMBL10156261 0.75 NSD2 (0.41) MAPTALDH1A1KDM4ERXFP1TP53
SCHEMBL13255403 0.74 CCR1 (0.51) MAPTALDH1A1KDM4ERXFP1TP53
SCHEMBL16533516 0.74 MEN1 (0.46) MAPTALDH1A1KDM4ERXFP1HTT
SCHEMBL23233126 0.74 KDM4E (0.51) MAPTALDH1A1KDM4ERXFP1TP53
SCHEMBL620812 0.74 KDM4E (0.57) MAPTALDH1A1KDM4ERXFP1TP53
SCHEMBL4882694 0.73 MAPT (0.52) PKMMAPTALDH1A1KDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9034303-B2 Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof ZURAWSKI JR VINCENT R (US) 2015-05-19 US disclosed
US-9034303-B2 Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof ZURAWSKI JR VINCENT R (US) 2015-05-19 US disclosed
US-20140186280-A1 NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF VARINEL INC (US) 2014-07-03 US disclosed
US-20140186280-A1 NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF VARINEL INC (US) 2014-07-03 US disclosed
WO-2012020389-A1 NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF VARINEL INC (US) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140186280-A1 NEUROPROTECTIVE AND NEURO-RESTORATIVE IRON CHELATORS AND MONOAMINE OXIDASE INHIBITORS AND USES THEREOF MAOA, MAOB, FECH PKM 1215/4885MAPT 1363/4885PTK2 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.